Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Iwamoto

Showing results (411-420 of 459) with videos related to

Pageof 46
Sort By:
Neuro-Oncology|March 8, 2011
A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03Fabio M Iwamoto, Kathleen R Lamborn, John G Kuhn, et al.
Research Square|November 24, 2025
Post-Chemoradiation Lymphopenia and Baseline Eosinophil Counts as Prognostic Markers in GlioblastomaEric Giannaris, Geoffrey Sedor, Catherine S Spina, et al.
BMC Cancer|May 28, 2026
Eosinophil counts as a prognostic marker in glioblastoma: a retrospective cohort studyEric Giannaris, Geoffrey Sedor, Catherine S Spina, et al.
Neuro-Oncology|March 5, 2010
Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02)Fabio M Iwamoto, Kathleen R Lamborn, H Ian Robins, et al.
Journal of Neuro-Oncology|June 29, 2011
Longitudinal prospective study of matrix metalloproteinase-9 as a serum marker in gliomasFabio M Iwamoto, Andreas F Hottinger, Sasan Karimi, et al.
Neuro-Oncology|August 12, 2011
Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomasFabio M Iwamoto, Andreas F Hottinger, Sasan Karimi, et al.
Annals of Neurology|March 11, 2011
YKL-40 and MMP-9 as serum markers for patients with primary central nervous system lymphomaAndreas F Hottinger, Fabio M Iwamoto, Sasan Karimi, et al.
Neuro-Oncology|June 14, 2024
NRG-BN002: Phase I study of ipilimumab, nivolumab, and the combination in patients with newly diagnosed glioblastomaAndrew E Sloan, Kathryn Winter, Mark R Gilbert, et al.
Scientific Reports|January 9, 2021
Consequence of aging at Au/HTM/perovskite interface in triple cation 3D and 2D/3D hybrid perovskite solar cellsZubair Ahmad, Arti Mishra, Sumayya M Abdulrahim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 21, 2010
Scale to predict survival after surgery for recurrent glioblastoma multiformeJohn K Park, Tiffany Hodges, Leopold Arko, et al.
Pageof 46

Showing results (411-420 of 459) with videos related to

Sort By:
Pageof 46
Neuro-Oncology|March 8, 2011
A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03Fabio M Iwamoto, Kathleen R Lamborn, John G Kuhn, et al.
Research Square|November 24, 2025
Post-Chemoradiation Lymphopenia and Baseline Eosinophil Counts as Prognostic Markers in GlioblastomaEric Giannaris, Geoffrey Sedor, Catherine S Spina, et al.
BMC Cancer|May 28, 2026
Eosinophil counts as a prognostic marker in glioblastoma: a retrospective cohort studyEric Giannaris, Geoffrey Sedor, Catherine S Spina, et al.
Neuro-Oncology|March 5, 2010
Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02)Fabio M Iwamoto, Kathleen R Lamborn, H Ian Robins, et al.
Journal of Neuro-Oncology|June 29, 2011
Longitudinal prospective study of matrix metalloproteinase-9 as a serum marker in gliomasFabio M Iwamoto, Andreas F Hottinger, Sasan Karimi, et al.
Neuro-Oncology|August 12, 2011
Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomasFabio M Iwamoto, Andreas F Hottinger, Sasan Karimi, et al.
Annals of Neurology|March 11, 2011
YKL-40 and MMP-9 as serum markers for patients with primary central nervous system lymphomaAndreas F Hottinger, Fabio M Iwamoto, Sasan Karimi, et al.
Neuro-Oncology|June 14, 2024
NRG-BN002: Phase I study of ipilimumab, nivolumab, and the combination in patients with newly diagnosed glioblastomaAndrew E Sloan, Kathryn Winter, Mark R Gilbert, et al.
Scientific Reports|January 9, 2021
Consequence of aging at Au/HTM/perovskite interface in triple cation 3D and 2D/3D hybrid perovskite solar cellsZubair Ahmad, Arti Mishra, Sumayya M Abdulrahim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 21, 2010
Scale to predict survival after surgery for recurrent glioblastoma multiformeJohn K Park, Tiffany Hodges, Leopold Arko, et al.
Pageof 46